EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY-NC 4.0

Impact of switching from bisphosphonates to denosumab, teriparatide, or romosozumab in patients with postmenopausal osteoporosis: a case–control study

Toshitaka Yukishima, Kosuke Ebina, Yuki Etani, Takaaki Noguchi, Shin-Ichiro Ohmura, Ken Nakata, Seiji Okada, Tomonori Kobayakawa

Osteoporosis International · 2025-03 · 36 (3) · 531-538

DOI: 10.1007/s00198-025-07386-4 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Osteoporosis International, online erschienen am 16.01.2025. Verfasst von Toshitaka Yukishima und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Rheumatology, Seirei Hamamatsu General Hospital, 2-12-12 Sumiyoshi, Chuo-Ku, Hamamatsu, Shizuoka, 430-8558, Japan. Hauptthemen laut MEDLINE: Osteoporosis, Postmenopausal, Bone Density Conservation Agents, Drug Substitution, Diphosphonates. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Osaka University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This case-control study investigated the impact of switching from bisphosphonates to denosumab, teriparatide, or romosozumab in postmenopausal osteoporosis. Romosozumab demonstrated the most significant improvements in bone mineral density, particularly in the lumbar spine and total hip, by reducing bone resorption and increasing bone formation markers. PURPOSE: To investigate the impact of switching from bisphosphonates (BP) to denosumab (DMAb), teriparatide (TPTD), or romosozumab (ROMO) in postmenopausal osteoporosis. METHODS: This retrospective, case-controlled, multicenter study included 389 patients who switched from BP to DMAb, TPTD, or ROMO due to treatment inefficacy. Propensity score matching was used to align patient backgrounds, resulting in 45 patients per group. Baseline characteristics included a mean age of 73.8 years, prior BP treatment duration of 37.1 months, and bone mineral density (BMD) T-scores of -2.8 in the lumbar spine (LS), -2.5 in the total hip (TH), and -2.7 in femoral neck (FN). BMD and bone turnover markers were assessed over 12 months. RESULTS: Following the switch from BP, the ROMO group demonstrated a dual effect of decreased bone resorption and increased bone formation markers. The TPTD group exhibited the highest increases in both markers, while the DMAb group suppressed both. After 12 months, the ROMO group demonstrated significantly greater BMD increases in the LS (11.4%) compared to the DMAb (6.3%; p < 0.001) and TPTD (5.9%; p < 0.001) groups. Additionally, the ROMO group showed greater increases in the TH (3.3%) than TPTD group (0.8%; p < 0.01). Only the ROMO group showed a significant BMD increase in the FN (2.0%; p < 0.01 from baseline). CONCLUSION: Significant BMD increases were observed in the LS for all groups, in the TH for the ROMO and DMAb groups, and in the FN for the ROMO group. ROMO showed the most substantial BMD improvements following BP therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Osteoporosis, PostmenopausalBone Density Conservation AgentsDrug SubstitutionDiphosphonatesHumansFemaleDenosumabAgedBone DensityCase-Control StudiesTeriparatideRetrospective StudiesLumbar VertebraeAged, 80 and overMiddle AgedAntibodies, MonoclonalBiomarkersHip JointBone Remodeling

Stichwörter der Autor:innen

BisphosphonatesBone mineral densityDenosumabRomosozumabTeriparatide

Substanzen

Bone Density Conservation AgentsDenosumabTeriparatideromosozumabDiphosphonatesAntibodies, MonoclonalBiomarkers

Autor:innen und Institutionen

  • Department of Rheumatology, Seirei Hamamatsu General Hospital, 2-12-12 Sumiyoshi, Chuo-Ku, Hamamatsu, Shizuoka, 430-8558, Japan.
  • Kobayakawa Orthopaedics and Rheumatologic Clinic, 1969 Kuno, Fukuroi, Shizuoka, 437-0061, Japan.
  • Department of Orthopaedic Surgery, Osaka University Graduate School of Medicine, 2-2 Yamada-Oka, Suita, Osaka, 565-0871, Japan. k-ebina@ort.med.osaka-u.ac.jp.
  • Department of Sports Medical Biomechanics, Osaka University Graduate School of Medicine, 2-2 Yamada-Oka, Suita, Osaka, 565-0871, Japan. k-ebina@ort.med.osaka-u.ac.jp.
  • Department of Sports Medical Biomechanics, Osaka University Graduate School of Medicine, 2-2 Yamada-Oka, Suita, Osaka, 565-0871, Japan.
  • Department of Orthopaedic Surgery, Osaka University Graduate School of Medicine, 2-2 Yamada-Oka, Suita, Osaka, 565-0871, Japan.

Förderung

  • Osaka University

Zitieren

APA

Yukishima, T., Ebina, K., Etani, Y., Noguchi, T., Ohmura, S. I., Nakata, K., Okada, S., & Kobayakawa, T. (2025). Impact of switching from bisphosphonates to denosumab, teriparatide, or romosozumab in patients with postmenopausal osteoporosis: a case–control study. Osteoporosis International, 36(3), 531-538. https://doi.org/10.1007/s00198-025-07386-4

Vancouver

Yukishima T, Ebina K, Etani Y, Noguchi T, Ohmura SI, Nakata K, et al. Impact of switching from bisphosphonates to denosumab, teriparatide, or romosozumab in patients with postmenopausal osteoporosis: a case–control study. Osteoporosis International. 2025;36(3):531-538. doi:10.1007/s00198-025-07386-4

BibTeX
@article{Yukishima2025,
  author = {Yukishima, Toshitaka and Ebina, Kosuke and Etani, Yuki and Noguchi, Takaaki and Ohmura, Shin-Ichiro and Nakata, Ken and Okada, Seiji and Kobayakawa, Tomonori},
  title = {Impact of switching from bisphosphonates to denosumab, teriparatide, or romosozumab in patients with postmenopausal osteoporosis: a case–control study},
  journal = {Osteoporosis International},
  year = {2025},
  volume = {36},
  number = {3},
  pages = {531--538},
  doi = {10.1007/s00198-025-07386-4}
}
Kostenlos starten →